Evidence map›Paper›PMID 38028059›Full record

ArticleClinical case reports2023

Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.

Franziska Wachter, Yana Pikman, Jacob Bledsoe, Malika Kapadia, Susanne Baumeister, Jared Rowe, Akiko Shimamura, Andrew E Place, Susan Prockop, Jennifer Whangbo and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Franziska WachterDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.ORCID https://orcid.org/0000-0001-9185-3612
Yana PikmanDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Jacob BledsoeDepartment of Pathology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA.
Malika KapadiaDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Susanne BaumeisterDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Jared RoweDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Akiko ShimamuraDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Andrew E PlaceDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Susan ProckopDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Jennifer WhangboDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Leslie LehmannDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
John HoranDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Jessica PollardDivision of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.

Funding

Systems Biology of Bone Marrow Failure and MDS for Precision MedicineRC2DK122533 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FIGUEROA, MARIA EUGENIA, FLEMING, MARK D · 2019 to 2023
$6.4M
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapyK08CA222684 · NCI · DANA-FARBER CANCER INST · PI PIKMAN, YANA · 2018 to 2022
$886k
NCI NIH HHS K08 CA222684NIDDK NIH HHS RC2 DK122533
6 · The paper itself

Abstract

Treatment of recurrent myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) remains challenging. We present a 4-year-old girl experiencing early MDS relapse post-HCT treated with a multimodal strategy encompassing a second HCT and innovative targeted therapies. We underscore the potential of a comprehensive treatment approach in managing recurrent pediatric MDS.

Indexed as

disease controlhematopoietic stem cell transplantationmyelodysplastic syndromesrelapse

Identifiers

PMID38028059
PMCPMC10665583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.